Alnylam Pharmaceuticals (ALNY) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Alnylam Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$1.83B

Latest Revenue (Q)

$420.15M

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Alnylam Pharmaceuticals Revenue by Period

Alnylam Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$1.83B	76.23%
2022-12-31	$1.04B	22.88%
2021-12-31	$844.29M	71.31%
2020-12-31	$492.85M	124.28%
2019-12-31	$219.75M	193.36%
2018-12-31	$74.91M	-16.69%
2017-12-31	$89.91M	90.66%
2016-12-31	$47.16M	14.75%
2015-12-31	$41.10M	-18.72%
2014-12-31	$50.56M	7.20%
2013-12-31	$47.17M	-29.31%
2012-12-31	$66.72M	-19.37%
2011-12-31	$82.76M	-17.28%
2010-12-31	$100.04M	-0.49%
2009-12-31	$100.53M	4.54%
2008-12-31	$96.16M	88.94%
2007-12-31	$50.90M	89.00%
2006-12-31	$26.93M	371.13%
2005-12-31	$5.72M	33.61%
2004-12-31	$4.28M	2330.68%
2003-12-31	$176.00K	100.00%
2002-12-31	-	-

Alnylam Pharmaceuticals generated $1.83B in revenue during NA 2023, up 76.23% compared to the previous quarter, and up 2440.72% compared to the same period a year ago.

Alnylam Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$420.15M	-36.32%
2024-06-30	$659.83M	33.48%
2024-03-31	$494.33M	12.42%
2023-12-31	$439.72M	-41.41%
2023-09-30	$750.53M	135.46%
2023-06-30	$318.75M	-0.17%
2023-03-31	$319.29M	-4.70%
2022-12-31	$335.04M	26.76%
2022-09-30	$264.31M	17.56%
2022-06-30	$224.82M	5.42%
2022-03-31	$213.26M	-17.51%
2021-12-31	$258.54M	37.79%
2021-09-30	$187.63M	-14.93%
2021-06-30	$220.55M	24.21%
2021-03-31	$177.57M	8.56%
2020-12-31	$163.56M	29.96%
2020-09-30	$125.85M	21.06%
2020-06-30	$103.96M	4.51%
2020-03-31	$99.48M	38.78%
2019-12-31	$71.68M	2.31%
2019-09-30	$70.06M	56.69%
2019-06-30	$44.71M	34.30%
2019-03-31	$33.29M	58.29%
2018-12-31	$21.03M	916.58%
2018-09-30	$2.07M	-93.08%
2018-06-30	$29.91M	36.57%
2018-03-31	$21.90M	-42.26%
2017-12-31	$37.92M	121.83%
2017-09-30	$17.10M	7.31%
2017-06-30	$15.93M	-15.97%
2017-03-31	$18.96M	8.63%
2016-12-31	$17.45M	27.86%
2016-09-30	$13.65M	56.75%
2016-06-30	$8.71M	18.57%
2016-03-31	$7.34M	-2.73%
2015-12-31	$7.55M	19.40%
2015-09-30	$6.32M	-27.18%
2015-06-30	$8.69M	-53.15%
2015-03-31	$18.54M	-22.82%
2014-12-31	$24.02M	118.91%
2014-09-30	$10.97M	50.40%
2014-06-30	$7.29M	-11.84%
2014-03-31	$8.28M	-23.71%
2013-12-31	$10.85M	20.64%
2013-09-30	$8.99M	3.50%
2013-06-30	$8.69M	-53.40%
2013-03-31	$18.64M	119.45%
2012-12-31	$8.49M	-49.31%
2012-09-30	$16.76M	-19.75%
2012-06-30	$20.88M	1.44%
2012-03-31	$20.59M	0.65%
2011-12-31	$20.45M	-1.62%
2011-09-30	$20.79M	0.86%
2011-06-30	$20.61M	-1.35%
2011-03-31	$20.90M	-1.39%
2010-12-31	$21.19M	-23.41%
2010-09-30	$27.67M	3.95%
2010-06-30	$26.62M	8.36%
2010-03-31	$24.56M	-7.74%
2009-12-31	$26.63M	9.80%
2009-09-30	$24.25M	-1.43%
2009-06-30	$24.60M	-1.82%
2009-03-31	$25.06M	2.68%
2008-12-31	$24.40M	-5.17%
2008-09-30	$25.73M	7.98%
2008-06-30	$23.83M	7.39%
2008-03-31	$22.19M	21.72%
2007-12-31	$18.23M	-

Alnylam Pharmaceuticals generated $420.15M in revenue during Q3 2024, up -36.32% compared to the previous quarter, and up 131.81% compared to the same period a year ago.

Alnylam Pharmaceuticals Revenue Breakdown

Alnylam Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 18
GIVLAARI	$219.25M	-	-	-	-
Product	$1.24B	$894.33M	$662.14M	$361.52M	$12.54M
Royalty	-	$8.18M	$1.20M	-	-

Alnylam Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (84.99%), and GIVLAARI (15.01%).

Quarterly Revenue by Product

Product/Service	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 19
Product	$420.15M	$410.09M	$365.16M	$346.29M	$313.15M	$305.70M	$276.33M	$261.68M	$232.27M	$213.51M	$186.87M	$198.51M	$167.04M	$160.81M	$135.77M	$112.84M	$99.21M	$26.29M	-	-
ONPATTRO	$50.29M	$77.24M	$69.22M	$81.59M	$66.53M	$66.66M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
GIVLAARI	$71.04M	$62.13M	$58.06M	$165.10M	$54.15M	$11.00M	$5.27M	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	$7.21M	$6.50M	$2.71M	$2.74M	$2.28M	$442.00K	$396.00K	$453.00K	$347.00K	-	-	-	-	-	-

Alnylam Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (77.59%), GIVLAARI (13.12%), and ONPATTRO (9.29%).

Alnylam Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
UNITED STATES	$411.17M	$27.70M	$18.88M	$151.57M	$116.45M
Europe	$210.92M	$37.91M	$38.95M	$333.00K	-
Non-US Or Europe	$75.77M	$4.17M	$1.76M	$46.75M	-
Non-US	-	-	-	-	$50.09M

Alnylam Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (58.92%), Europe (30.22%), and Non-US Or Europe (10.86%).

Quarterly Revenue by Country

Country	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
Europe	$65.14M	$56.76M	$44.69M	$135.02M	$50.37M	$12.22M	$13.31M	$12.82M	$9.35M	$7.59M	$8.16M	$11.72M	$9.66M	$9.83M	$7.74M	$33.09M	$30.48M	$25.36M	$21.17M	-
Non-US Or Europe	$24.79M	$24.89M	$21.27M	$55.02M	$15.76M	$3.20M	$1.79M	$2.23M	$698.00K	$223.00K	$1.02M	$24.67M	$18.05M	$16.54M	$11.83M	$14.19M	$13.01M	-	-	-
UNITED STATES	$168.66M	$148.46M	$130.24M	$279.81M	$113.51M	$8.79M	$9.06M	$8.78M	$6.38M	$7.12M	$5.41M	$5.72M	$5.24M	$6.51M	$1.41M	$43.08M	$39.03M	$40.93M	$42.47M	$35.91M
Non-US	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$11.25M	$8.30M	$20.04M

Alnylam Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (65.22%), Europe (25.19%), and Non-US Or Europe (9.59%).

Alnylam Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
INCY	Incyte	$3.70B	$962.99M
BMRN	BioMarin Pharmaceutical	$2.42B	$733.87B
UTHR	United Therapeutics	$2.33B	$748.90M
EXEL	Exelixis	$1.83B	$478.06M
ALNY	Alnylam Pharmaceuticals	$1.83B	$420.15M
HALO	Halozyme Therapeutics	$829.25M	$290.08M
RARE	Ultragenyx Pharmaceutical	$434.25M	$147.03M
AMLX	Amylyx Pharmaceuticals	$380.79M	$416.00K
APLS	Apellis Pharmaceuticals	$366.28M	$176.57M
BPMC	Blueprint Medicines	$249.38M	$128.18M
WVE	Wave Life Sciences	$113.31M	$19.69M
KRYS	Krystal Biotech	$50.70M	$83.84M
PRQR	ProQR Therapeutics	$6.38M	$4.48M
MDGL	Madrigal Pharmaceuticals	-	$62.17M
DAWN	Day One Biopharmaceuticals	-	$20.07M

ALNY Revenue FAQ

What is Alnylam Pharmaceuticals’s yearly revenue?

Alnylam Pharmaceuticals's yearly revenue for 2023 was $1.83B, representing an increase of 76.23% compared to 2022. The company's yearly revenue for 2022 was $1.04B, representing an increase of 22.88% compared to 2021. ALNY's yearly revenue for 2021 was $844.29M, representing an increase of 71.31% compared to 2020.

What is Alnylam Pharmaceuticals’s quarterly revenue?

Alnylam Pharmaceuticals's quarterly revenue for Q3 2024 was $420.15M, a -36.32% decrease from the previous quarter (Q2 2024), and a -44.02% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $659.82M, a 33.48% increase from the previous quarter (Q1 2024), and a 107.00% increase year-over-year (Q2 2023). ALNY's quarterly revenue for Q1 2024 was $494.33M, a 12.42% increase from the previous quarter (Q4 2023), and a 54.82% increase year-over-year (Q1 2023).

What is Alnylam Pharmaceuticals’s revenue growth rate?

Alnylam Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 116.55%, and for the last 5 years (2019-2023) was 731.99%.

What are Alnylam Pharmaceuticals’s revenue streams?

Alnylam Pharmaceuticals's revenue streams in c 23 are GIVLAARI, and Product. GIVLAARI generated $219.25M in revenue, accounting 15.01% of the company's total revenue Product generated $1.24B in revenue, accounting 84.99% of the company's total revenue, up 38.82% year-over-year.

What is Alnylam Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Alnylam Pharmaceuticals was Product. This segment made a revenue of $1.24B, representing 84.99% of the company's total revenue.